Bausch + Lomb (BLCO) Competitors

Bausch + Lomb (NYSE:BLCO) and Zimmer Biomet (NYSE:ZBH) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, valuation, earnings, risk and analyst recommendations.

Does the media refer more to BLCO or ZBH?

In the previous week, Zimmer Biomet had 3 more articles in the media than Bausch + Lomb. MarketBeat recorded 8 mentions for Zimmer Biomet and 5 mentions for Bausch + Lomb. Zimmer Biomet's average media sentiment score of 0.69 beat Bausch + Lomb's score of 0.58 indicating that Zimmer Biomet is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bausch + Lomb	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zimmer Biomet	5 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has stronger valuation & earnings, BLCO or ZBH?

Zimmer Biomet has higher revenue and earnings than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than Zimmer Biomet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch + Lomb	$4.79B	1.04	-$317M	-$1.03	-13.65
Zimmer Biomet	$7.68B	2.50	$903.70M	$4.52	21.43

Do analysts recommend BLCO or ZBH?

Bausch + Lomb currently has a consensus target price of $15.45, suggesting a potential upside of 9.96%. Zimmer Biomet has a consensus target price of $111.39, suggesting a potential upside of 15.01%. Given Zimmer Biomet's stronger consensus rating and higher probable upside, analysts clearly believe Zimmer Biomet is more favorable than Bausch + Lomb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch + Lomb	1 Sell rating(s)	8 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.17
Zimmer Biomet	2 Sell rating(s)	9 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.35

Do insiders and institutionals have more ownership in BLCO or ZBH?

11.1% of Bausch + Lomb shares are held by institutional investors. Comparatively, 88.9% of Zimmer Biomet shares are held by institutional investors. 0.8% of Bausch + Lomb shares are held by company insiders. Comparatively, 1.4% of Zimmer Biomet shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Is BLCO or ZBH more profitable?

Zimmer Biomet has a net margin of 11.86% compared to Bausch + Lomb's net margin of -7.50%. Zimmer Biomet's return on equity of 12.73% beat Bausch + Lomb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch + Lomb	-7.50%	2.62%	1.28%
Zimmer Biomet	11.86%	12.73%	7.34%

Which has more volatility & risk, BLCO or ZBH?

Bausch + Lomb has a beta of 0.62, indicating that its share price is 38% less volatile than the S&P 500. Comparatively, Zimmer Biomet has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500.

Summary

Zimmer Biomet beats Bausch + Lomb on 16 of the 16 factors compared between the two stocks.